Zare Jeddi Maryam, Hopf Nancy B, Louro Henriqueta, Viegas Susana, Galea Karen S, Pasanen-Kase Robert, Santonen Tiina, Mustieles Vicente, Fernandez Mariana F, Verhagen Hans, Bopp Stephanie K, Antignac Jean Philippe, David Arthur, Mol Hans, Barouki Robert, Audouze Karine, Duca Radu-Corneliu, Fantke Peter, Scheepers Paul, Ghosh Manosij, Van Nieuwenhuyse An, Lobo Vicente Joana, Trier Xenia, Rambaud Loïc, Fillol Clémence, Denys Sebastien, Conrad André, Kolossa-Gehring Marike, Paini Alicia, Arnot Jon, Schulze Florian, Jones Kate, Sepai Ovnair, Ali Imran, Brennan Lorraine, Benfenati Emilio, Cubadda Francesco, Mantovani Alberto, Bartonova Alena, Connolly Alison, Slobodnik Jaroslav, Bruinen de Bruin Yuri, van Klaveren Jacob, Palmen Nicole, Dirven Hubert, Husøy Trine, Thomsen Cathrine, Virgolino Ana, Röösli Martin, Gant Tim, von Goetz Natalie, Bessems Jos
National Institute for Public Health and the Environment (RIVM), the Netherlands.
Centre for Primary Care and Public Health (Unisanté), University of Lausanne, Switzerland.
Environ Int. 2022 Oct;168:107476. doi: 10.1016/j.envint.2022.107476. Epub 2022 Aug 28.
Human biomonitoring (HBM) is a crucial approach for exposure assessment, as emphasised in the European Commission's Chemicals Strategy for Sustainability (CSS). HBM can help to improve chemical policies in five major key areas: (1) assessing internal and aggregate exposure in different target populations; 2) assessing exposure to chemicals across life stages; (3) assessing combined exposure to multiple chemicals (mixtures); (4) bridging regulatory silos on aggregate exposure; and (5) enhancing the effectiveness of risk management measures. In this strategy paper we propose a vision and a strategy for the use of HBM in chemical regulations and public health policy in Europe and beyond. We outline six strategic objectives and a roadmap to further strengthen HBM approaches and increase their implementation in the regulatory risk assessment of chemicals to enhance our understanding of exposure and health impacts, enabling timely and targeted policy interventions and risk management. These strategic objectives are: 1) further development of sampling strategies and sample preparation; 2) further development of chemical-analytical HBM methods; 3) improving harmonisation throughout the HBM research life cycle; 4) further development of quality control / quality assurance throughout the HBM research life cycle; 5) obtain sustained funding and reinforcement by legislation; and 6) extend target-specific communication with scientists, policymakers, citizens and other stakeholders. HBM approaches are essential in risk assessment to address scientific, regulatory and societal challenges. HBM requires full and strong support from the scientific and regulatory domain to reach its full potential in public and occupational health assessment and in regulatory decision-making.
正如欧盟委员会《可持续发展化学品战略》（CSS）所强调的，人体生物监测（HBM）是暴露评估的关键方法。HBM有助于在五个主要关键领域改进化学品政策：（1）评估不同目标人群的内部暴露和累积暴露；（2）评估生命各阶段的化学品暴露；（3）评估多种化学品（混合物）的联合暴露；（4）弥合累积暴露方面的监管隔阂；（5）提高风险管理措施的有效性。在本战略文件中，我们提出了在欧洲及其他地区将HBM用于化学品监管和公共卫生政策的愿景和战略。我们概述了六个战略目标和一个路线图，以进一步加强HBM方法，并在化学品监管风险评估中增加其应用，从而增进我们对暴露和健康影响的理解，实现及时且有针对性的政策干预和风险管理。这些战略目标是：（1）进一步开发采样策略和样品制备方法；（2）进一步开发化学分析HBM方法；（3）在整个HBM研究生命周期内提高协调一致性；（4）在整个HBM研究生命周期内进一步发展质量控制/质量保证；（5）通过立法获得持续资金支持并加强；（6）扩大与科学家、政策制定者、公民和其他利益相关者的针对性沟通。HBM方法在风险评估中对于应对科学、监管和社会挑战至关重要。HBM需要科学和监管领域的充分有力支持，才能在公共和职业健康评估以及监管决策中充分发挥其潜力。
